1064684-71-4

Usage

Uses

Used in Pharmaceutical Industry:
(R)-2-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy](phenoxy)phosphorylaminopropionic acid isopropyl ester is used as a reagent for synthesizing β-D-2''-Deoxy-2''-α-fluoro-2''-β-C-methyluridine nucleotide. (R)-2-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy](phenoxy)phosphorylaminopropionic acid isopropyl ester can selectively inhibit Hepatitis C virus (HCV) NS5B polymerase, making it a potential target for developing therapies for HCV.
Used in Research and Development:
(R)-2-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy](phenoxy)phosphorylaminopropionic acid isopropyl ester is also used as an impurity in the study and development of Sofosbuvir (P839640). This allows researchers to better understand the compound's properties and potential applications in the pharmaceutical industry.

Upstream product

• 863329-66-2 2'-deoxy-2'-fluoro-2'-methyluridine 
• 1627824-09-2 (R)-2-((R)-(2,3,4,5,6-pentafluorophenoxy)phenoxyphosphorylamino)propionic acid isopropyl ester 

Relevant academic research and scientific papers

The protecting-group free selective 3′-functionalization of nucleosides

The direct and chemoselective 3′-phosphoramidation, phosphorylation and acylation of nucleosides are described. Upon the discovery of a novel 3′-phosphorylamidation of therapeutic nucleoside analogues with DBU, we explored the mechanism of this rare selectivity through a combination of NMR spectroscopy and computational studies. The NMR and computational findings allowed us to develop a predictive computational model that accurately assesses the potential for 3′-functionalization for a broad range of nucleosides and nucleoside mimetics. The synthetic utility of this model was exemplified by demonstration on a broad scope of nucleosides and electrophiles yielding targets that were previously only accessible via a protection/deprotection sequence or an enzymatic approach.

NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS

Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.